Laigo Bio, a Dutch biotechnology firm, has successfully completed the second close of its seed financing round, securing an additional $6.3 million. This new capital, which brings the company's total seed funding to $19.5 million, was led by new investor Biovance Capital and existing backer Kurma Partners. The funds are earmarked to advance the company's proprietary protein degradation platform for developing new cancer and autoimmune disease therapies.
Strategic Investment to Propel Clinical Development
The financing round includes a $4.6 million contribution from new co-lead investor Biovance Capital, with an additional $1.7 million provided by existing co-lead Kurma Partners. This capital infusion is designated to accelerate Laigo's lead oncology programs based on its Surface Removal Targeting Chimeras (SureTACs) platform towards clinical trials. The investment will also bolster the advancement of three other candidate programs targeting autoimmune conditions and graft rejection.
Dr. Matthew Baker, Chief Executive Officer of Laigo Bio, stated that the funding validates the potential of the SureTACs platform to create first-in-class therapies. He emphasized that the support from Biovance Capital and Kurma Partners will be instrumental in advancing their clinical and discovery efforts. Dr. Baker also formally welcomed Dr. João Incio of Biovance Capital to the company's Board of Directors.
A Novel Approach to Protein Degradation
Laigo's innovative SureTACs platform generates bispecific antibodies that selectively target and eliminate disease-causing proteins on the cell membrane. These molecules work by pairing a specific E3 ligase with the target protein, which initiates a natural cellular process called ubiquitination and subsequent degradation. This mechanism allows for the precise removal of proteins that drive disease progression with a high degree of specificity.
A key advantage of this technology is its ability to address membrane proteins that have historically been considered "undruggable" by conventional therapeutic methods. By inducing degradation, SureTACs can achieve a more profound and lasting inhibition of disease pathways. This targeted approach is designed to maximize therapeutic impact on affected tissues while sparing healthy cells and minimizing potential side effects.
Investor Confidence and Market Potential
Dr. João Incio, General Partner at Biovance Capital, expressed strong confidence in Laigo's technology, highlighting its remarkable efficacy and selectivity in preclinical studies. He noted the platform's improved safety profile and its phenomenal potential to explore a new universe of therapeutic targets. This capability to address previously inaccessible disease drivers was a key factor in Biovance Capital's decision to invest in the company.
The company is supported by a robust syndicate of prominent international investors beyond the co-leads. This consortium includes Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, and the Oncode Bridge Fund, among others. Such broad backing from specialized life sciences venture firms underscores the significant commercial and scientific potential attributed to Laigo's pioneering platform.
This latest $6.3 million funding extension marks a significant milestone for Laigo Bio, strengthening its financial foundation to pursue ambitious clinical goals. The investment not only validates the scientific promise of the SureTACs platform but also equips the company to accelerate its development pipeline. Laigo is now better positioned to translate its innovative protein degradation technology into transformative treatments for patients with cancer and autoimmune disorders.